Allarity Therapeutics, Inc. Accretion Expense
Allarity Therapeutics, Inc. (ALLR) reported Accretion Expense of $166.00 thousand for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-08.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2024-03-08
- Allarity Therapeutics, Inc. accretion expense for the quarter ending 2023-12-31 was $120.00K, a 823.08% increase year-over-year.
- Allarity Therapeutics, Inc. accretion expense for the quarter ending 2023-09-30 was $16.00K, a 23.08% increase year-over-year.
- Allarity Therapeutics, Inc. accretion expense for the quarter ending 2023-06-30 was $15.00K, a 25.00% increase year-over-year.
- Allarity Therapeutics, Inc. accretion expense for the quarter ending 2023-03-31 was $15.00K, a 15.38% increase year-over-year.
- Allarity Therapeutics, Inc. accretion expense for fiscal 2023 was $166.00K, a 225.49% increase from fiscal 2022.
- Allarity Therapeutics, Inc. accretion expense for fiscal 2022 was $51.00K.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $120.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $136.00K derived: sum of 2 quarters · filed 2024-03-08 | $151.00K derived: sum of 3 quarters · filed 2024-03-08 | $166.00K 10-K · filed 2024-03-08 |
| 2023-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $31.00K derived: sum of 2 quarters · filed 2023-11-14 | $46.00K 10-Q · filed 2023-11-14 | $59.00K derived: sum of 4 quarters · filed 2024-03-08 |
| 2023-06-30 | $15.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $30.00K 10-Q · filed 2023-08-14 | $43.00K derived: sum of 3 quarters · filed 2024-03-08 | $56.00K derived: sum of 4 quarters · filed 2024-03-08 |
| 2023-03-31 | $15.00K 10-Q · filed 2023-05-11 | $28.00K derived: sum of 2 quarters · filed 2024-03-08 | $41.00K derived: sum of 3 quarters · filed 2024-03-08 | $53.00K derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-12-31 | $13.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $26.00K derived: sum of 2 quarters · filed 2024-03-08 | $38.00K derived: sum of 3 quarters · filed 2024-03-08 | $51.00K 10-K · filed 2024-03-08 |
| 2022-09-30 | $13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $25.00K derived: sum of 2 quarters · filed 2022-11-14 | $38.00K 10-Q · filed 2022-11-14 | $51.00K derived: sum of 4 quarters · filed 2022-11-14 |
| 2022-06-30 | $12.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-10-07 | $25.00K 10-Q · filed 2022-10-07 | $38.00K derived: sum of 3 quarters · filed 2022-11-14 | |
| 2022-03-31 | $13.00K 10-Q · filed 2022-05-27 | $26.00K derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-12-31 | $13.00K derived: 10-Q 12 month − 10-Q/A 9 month · filed 2022-11-14 | $51.00K 10-Q · filed 2022-11-14 | ||
| 2021-09-30 | $38.00K 10-Q/A · filed 2022-05-17 | |||
| 2020-12-31 | $51.00K 10-Q/A · filed 2022-05-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Pasithea Therapeutics Corp. (KTTA) | United States | $0.017B | -0.81 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B |